These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28748652)

  • 1. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
    Lau WCY; Li X; Wong ICK; Man KKC; Lip GYH; Leung WK; Siu CW; Chan EW
    J Thromb Haemost; 2017 Oct; 15(10):1923-1933. PubMed ID: 28748652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
    Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
    BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation.
    Lee KH; Park HW; Lee N; Hyun DY; Won J; Oh SS; Park HJ; Kim Y; Cho JY; Kim MC; Sim DS; Yoon HJ; Yoon NS; Kim KH; Hong YJ; Kim JH; Ahn Y; Jeong MH; Park JC; Cho JG
    Europace; 2017 Dec; 19(suppl_4):iv1-iv9. PubMed ID: 29220421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
    Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of bleeding with dabigatran in atrial fibrillation.
    Hernandez I; Baik SH; Piñera A; Zhang Y
    JAMA Intern Med; 2015 Jan; 175(1):18-24. PubMed ID: 25365537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
    Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.
    Lau WC; Chan EW; Cheung CL; Sing CW; Man KK; Lip GY; Siu CW; Lam JK; Lee AC; Wong IC
    JAMA; 2017 Mar; 317(11):1151-1158. PubMed ID: 28324091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin.
    Song X; Gandhi P; Gilligan AM; Arora P; Wang C; Henriques C; Sander S; Smith DM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):213-222. PubMed ID: 28649894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
    Lip GY; Keshishian A; Kamble S; Pan X; Mardekian J; Horblyuk R; Hamilton M
    Thromb Haemost; 2016 Oct; 116(5):975-986. PubMed ID: 27538358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
    Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
    J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation.
    Hernandez I; Zhang Y; Brooks MM; Chin PK; Saba S
    Stroke; 2017 Jan; 48(1):159-166. PubMed ID: 27909200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
    Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital Admissions, Costs, and 30-Day Readmissions Among Newly Diagnosed Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran Etexilate or Warfarin.
    Fonseca E; Sander SD; Hess GP; Ghosh S
    J Manag Care Spec Pharm; 2015 Nov; 21(11):1039-53. PubMed ID: 26521116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS; Singh S; Alexander GC; Heien H; Haas LR; Crown W; Shah ND
    BMJ; 2015 Apr; 350():h1857. PubMed ID: 25910928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation.
    Harel Z; McArthur E; Jeyakumar N; Sood MM; Garg AX; Silver SA; Dorian P; Blum D; Beaubien-Souligny W; Yan AT; Badve SV; Smyth B; Jun M; Jandoc R; Kitchlu A; Wald R
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1470-1479. PubMed ID: 34407990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.